Treatment for methamphetamine cardiovascular disease

Abstract

A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H 2 S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H 2 S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H 2 S donor may be sugammadex. The H 2 S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Wherefore, I/we claim: 
     
         1 . A method of treating or preventing methamphetamine-related endothelial dysfunction in a patient, comprising administering to the patient an effective dose of a pharmacologic composition comprising:
 a hydrogen sulfide (H 2 S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof; and   cystathionine gamma lyase (CSE), or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug, analog, or synthetic mRNA coded to increase CSE expression.   
     
     
         2 . The method of  claim 1  wherein the H 2 S donor is selected from the group consisting of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. 
     
     
         3 . The method of  claim 1 , wherein the therapeutic is administered in one of oral, intravenous, and transdermal pathways. 
     
     
         4 . The method of  claim 1 , wherein the H 2 S donor is administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg. 
     
     
         5 . The method of  claim 1 , wherein the H 2 S donor is administered exactly once in a dosage period, the dosage period being between 1 day and 30 days. 
     
     
         6 . The method of  claim 1 , wherein the therapeutic has an enteric coating. 
     
     
         7 . The method of  claim 1 , wherein the H 2 S donor is formulated for one of oral and peritoneal administration and is administered in a dosage of between 1.0 mg and 100.0 mg of H 2 S donor. 
     
     
         8 . A method of treating or preventing methamphetamine-related endothelial dysfunction in a patient comprising:
 administering to the patient an effective dose of a pharmacologic composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H 2 S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof,   wherein the H 2 S donor is selected from the group consisting of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones.   
     
     
         9 . The method of  claim 8 , wherein the therapeutic is administered in one of oral, intravenous, and transdermal pathways. 
     
     
         10 . The method of  claim 8 , wherein the H 2 S donor is administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg. 
     
     
         11 . The method of  claim 8 , wherein the H 2 S donor is administered exactly once in a dosage period, the dosage period being between 1 day and 30 days. 
     
     
         12 . The method of  claim 8 , wherein the therapeutic has an enteric coating. 
     
     
         13 . The method of  claim 8 , wherein the H 2 S donor is formulated for one of oral and peritoneal administration and is administered in a dosage of between 1.0 mg and 100.0 mg of H 2 S donor. 
     
     
         14 . A method of treating an endothelial dysfunction-related disease in a methamphetamine patient comprising:
 administering to the patient an effective dose of a pharmacologic composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H 2 S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof;   wherein the endothelial dysfunction-related disease is selected from the group consisting of atherosclerosis, hypertension, myocardial infarction, diabetes, and cardiovascular disease, or a precondition thereof.   
     
     
         15 . The method of  claim 14 , wherein the therapeutic further comprises cystathionine gamma lyase (CSE), or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug, analog, or synthetic mRNA coded to increase CSE expression. 
     
     
         16 . The method of  claim 14 , wherein the therapeutic is administered in one of oral, intravenous, and transdermal pathways.